AT
Ashok Thakur
About Ashok Thakur
Data last updated:
Ashok Thakur is a Director at Systole Remedies Private Limited (since 2025). The company operates in Pharma. Systole Remedies Private Limited reported revenue of ₹59.68 Cr (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 01 Oct 2025 | 2005 | ₹59.68 Cr (FY 2025) | Active |
Board colleagues of Ashok Thakur
| Name | DIN | Company | Designation |
|---|---|---|---|
| Harsimran Singh Kalra | 08445853 | Systole Remedies Private Limited | Additional Director |
| Jitender Mohan Kalra | 08544394 | Systole Remedies Private Limited | Additional Director |
| Mandeep Singh Kalra | 09240146 | Systole Remedies Private Limited | Additional Director |
| Pavneet Singh Kalra | 09239772 | Systole Remedies Private Limited | Additional Director |
| Pawan Kumar | 03336280 | Systole Remedies Private Limited | Person Incharge |
| Ravneet Singh | 08445822 | Systole Remedies Private Limited | Additional Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Ashok Thakur
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ashok Thakur
Ashok Thakur currently holds 1 directorship: Systole Remedies Private Limited (Director, since 01 Oct 2025, revenue ₹59.68 Cr (FY 2025)).
Ashok Thakur was first appointed on 01 Oct 2025 as Director at Systole Remedies Private Limited.
The current boards of Ashok Thakur's companies include Harsimran Singh Kalra (Systole Remedies Private Limited), Jitender Mohan Kalra (Systole Remedies Private Limited), Mandeep Singh Kalra (Systole Remedies Private Limited), Pavneet Singh Kalra (Systole Remedies Private Limited), Pawan Kumar (Systole Remedies Private Limited), Ravneet Singh (Systole Remedies Private Limited).